Constellation Pharmaceuticals Inc (NASDAQ:CNST) CFO Emma Reeve sold 65,626 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $30.91, for a total value of $2,028,499.66.
CNST stock traded down $0.91 during trading on Friday, reaching $30.91. The stock had a trading volume of 940,000 shares, compared to its average volume of 139,883. The firm has a market cap of $381.40 million, a PE ratio of -6.18 and a beta of 5.32. Constellation Pharmaceuticals Inc has a 52 week low of $4.01 and a 52 week high of $45.42. The stock’s 50 day moving average is $11.58 and its two-hundred day moving average is $10.07. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.44.
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. On average, research analysts anticipate that Constellation Pharmaceuticals Inc will post -2.99 EPS for the current year.
CNST has been the topic of a number of recent research reports. HC Wainwright increased their target price on Constellation Pharmaceuticals from $18.00 to $50.00 and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research downgraded Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada increased their target price on Constellation Pharmaceuticals to $42.00 and gave the company a “positive” rating in a report on Thursday. Robert W. Baird increased their target price on Constellation Pharmaceuticals from $17.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday. Finally, BMO Capital Markets increased their target price on Constellation Pharmaceuticals from $17.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $36.96.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Further Reading: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.